Financial Performance - The company's operating revenue for Q3 2022 reached ¥807,395,894.65, representing a year-on-year increase of 36.34%[7] - The net profit attributable to shareholders for Q3 2022 was ¥160,875,376.68, with a year-on-year increase of 28.59%[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥136,145,703.57, reflecting a year-on-year increase of 36.00%[7] - The company's operating revenue increased by 36.52% during the reporting period, driven by growth in both IoT solutions and traditional business segments[22] - Total operating revenue for the first three quarters of 2022 reached CNY 2,075,274,671.51, a 36.4% increase from CNY 1,520,143,956.41 in the same period of 2021[44] - Net profit for the third quarter of 2022 was CNY 464,543,504.50, down 33.7% from CNY 700,445,995.03 in the previous year[47] - The total comprehensive income attributable to the parent company was 463,660,821.15 CNY, a decrease from 722,641,850.20 CNY in the previous year, representing a decline of approximately 35.8%[49] - Basic and diluted earnings per share were both 1.46 CNY, down from 2.20 CNY in the same period last year, indicating a decrease of about 33.6%[49] Research and Development - Research and development expenses totaled ¥77,377,397.24 in Q3 2022, accounting for 9.58% of operating revenue, a decrease of 4.17 percentage points year-on-year[11] - Research and development expenses for the first three quarters amounted to CNY 211,246,026.69, an increase from CNY 174,004,095.97, representing a growth of 21.4%[44] Market Growth - The domestic market grew by 30.53% year-on-year, while the overseas market saw a growth of 54.02%[15] - The life sciences digital scenario revenue increased by 46.31% year-on-year, while the medical innovation digital scenario revenue grew by 29.52%[13] Assets and Liabilities - The total assets of the company at the end of Q3 2022 were ¥5,142,698,967.95, an increase of 4.96% compared to the end of the previous year[11] - As of September 30, 2022, the total assets of the company reached approximately RMB 5.14 billion, an increase from RMB 4.90 billion at the end of 2021, reflecting a growth of about 4.95%[36] - The company's current assets totaled approximately RMB 3.49 billion, compared to RMB 3.46 billion at the end of 2021, indicating a slight increase of around 0.70%[39] - The company's non-current assets totaled approximately RMB 1.66 billion, up from RMB 1.44 billion at the end of 2021, showing an increase of about 14.83%[39] - The total liabilities decreased to CNY 1,210,378,778.46 from CNY 1,261,079,904.20, reflecting a reduction of approximately 4.0%[44] - The company's total equity increased to CNY 3,932,320,189.49 from CNY 3,638,749,093.87, reflecting an increase of approximately 8.1%[44] Cash Flow - The cash flow from operating activities decreased by 56.30%, primarily due to an increase in cash payments for goods and services[27] - Cash inflow from operating activities totaled 1,958,373,149.95 CNY, compared to 1,894,103,983.24 CNY in the previous year, reflecting an increase of approximately 3.4%[53] - Net cash flow from operating activities was 193,535,402.24 CNY, a significant decrease of 56.3% from 442,839,649.28 CNY in the prior year[53] - Cash inflow from investment activities was 9,754,732,369.18 CNY, up from 5,001,698,658.93 CNY, marking an increase of approximately 94.5%[54] - The net cash flow from financing activities was -208,117,313.00 CNY, compared to -147,113,388.82 CNY in the previous year, indicating a decline of about 41.5%[54] Other Financial Metrics - The weighted average return on equity was 4.21%, an increase of 0.44 percentage points year-on-year[11] - The total comprehensive income decreased by 35.61%, mainly due to changes in net profit during the reporting period[26] - The company reported a significant decrease of 60.24% in notes receivable, mainly due to the maturity and acceptance of notes during the reporting period[22] - The company experienced a 44.44% decrease in taxes payable, mainly due to a reduction in income tax payable during the reporting period[22] - The company reported a foreign exchange impact on cash and cash equivalents of 32,144,292.63 CNY, compared to 8,681,857.50 CNY in the previous year, showing an increase of approximately 270.5%[54]
海尔生物(688139) - 2022 Q3 - 季度财报